The event will feature an overview of the ongoing Phase 3 REGAL trial of GPS (results expected by year-end) and a discussion of the unmet needs of AML patients in complete second remission (CR2).
The one-hour session, "Seeing Beyond Vision Loss: A Focus on Mental Health Resources for Patients with Retinal Disease," will ...
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, ...
Our three programs offer unique experiences to earn a medical degree. The University (Western Reserve 2) Program, our traditional four-year MD program, is our oldest and largest, offering an ...
Emma Guttman, MD, PhD, discusses the promising potential of rocatinlimab in targeting the OX40-OX40 ligand pathway for atopic dermatitis treatment. Trial investigator Emma Guttman, MD, PhD, chair of ...
David Lee Jobe, age 80, of Salem, passed away Monday, September 15, 2025 at Salem Health after an extended illness. He was born on May 24, 1945 in Carthage, MO, the son of the late Herman and Sybil ...
Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence ...
The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression. At the 22nd International Myeloma Society annual ...
Douglas Grossman, MD, PhD, is an investigator in Huntsman Cancer Institute's (HCI) Melanoma Program and a Professor in the Department of Dermatology at the University of Utah School of Medicine. He is ...
The FDA granted approval to nerandomilast, now Jascayd, for treating adults with idiopathic pulmonary fibrosis, marking the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback